Publication

Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings

Authored by:

Antillon M, Bilcke J, Paltiel AD, Pitzer VE

Full Citation:

Antillon M, Bilcke J, Paltiel AD, Pitzer VE 2017. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. Vaccine. 35.

View Publication

Additional key concepts from this publication:

The greatest cost savings from introducing new vaccines and increasing immunization coverage would occur in countries and regions with high disease burden and large populations.

Key Evidence: The first study of the cost-effectiveness of typhoid conjugate vaccines found that routinely immunizing infants at 9 months of age would actually save costs in 2 settings (Delhi, India and a rural area of Vietnam), due to high incidence or high hospitalization rates, and would be cost-effective in the study’s 3 other sites (in India and Kenya). Adding a one-time catch-up campaign for various older age groups would still save costs in the Delhi and Vietnam, and increase the cost-effectiveness in the others, making it economically justifiable.

From the VoICE Editors: The study incorporated herd effects into its model, looked only at the perspective of healthcare payers and assumed the use of a single dose vaccine at 1 international dollar.